Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Prime Medicine, Inc. Common Stock
PRMECurrent price
3.6 USD
-0.41 USD (-10.13%)
Last closed
3.96 USD
Company
www.primemedicine.com
ISIN
US74168J1016
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
492 127 104 USD
Yield for 12 month
-44.86 %
1Y
3Y
5Y
10Y
15Y
PRME
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company has a strategic research collaboration and license agreement with bristol myers squibb to develop and commercialize multiple prime edited ex vivo t-cell therapies. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts. Address: 21 Erie Street, Cambridge, MA, United States, 02139
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
12.8 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+5 210 000 USD
Current Quarter
+39 312 000 USD
Last Quarter
+591 000 USD
Current Year
-147 905 000 USD
Last Year
-6 804 000 USD
Current Quarter
+37 774 000 USD
Last Quarter
-724 000 USD
Key Figures PRME
1 year
3 years
5 years
10 years
EBITDA
-204 679 008 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-48.56 %
PEG Ratio
–
Return On Equity TTM
-99.58 %
Wall Street Target Price
12.8 USD
Revenue TTM
591 000 USD
Book Value
1.69 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
-86 725 000 USD
Earnings per share
-2.17 USD
Diluted Eps TTM
-2.17 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PRME
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History PRME
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation PRME
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
627.4811
Price Sales TTM
832.7024
Enterprise Value EBITDA
-3.1034
Price Book MRQ
2.5033
Financials PRME
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PRME
For 52 weeks
3.28 USD
9.86 USD
50 Day MA
3.87 USD
Shares Short Prior Month
16 715 788
200 Day MA
5.61 USD
Short Ratio
6.41
Shares Short
17 635 877
Short Percent
30.87 %
BeatStart